Treatment of temporomandibular joint internal derangement using MESNA injection.

ABSTRACT:

Introduction

The development of temporomandibular disorders specifically emphasizes the biochemical changes occurring in the synovial fluid at different stages of temporomandibular joint disease. Research has indicated that inflammation may be a primary reason behind the pain and dysfunction in temporomandibular joint diseases. Since its clearance several years ago, MESNA (sodium 2-mercaptoethanesulfonate) has been used in various formulations as a mucolytic drug in the respiratory domain. It operates by disrupting the disulfide bonds present between polypeptide chains within mucus. MESNA exhibits minimal tissue distribution, with the material being swiftly and thoroughly eliminated via the kidneys.

Objectives

To assess the efficacy of injecting MESNA directly into the Tempo

SUBMITTER: Mosleh AA 

PROVIDER: S-EPMC11299281 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature